Evidence map›Paper›PMID 38341147›Full record

ArticleJournal of the American Academy of Dermatology2024

Associations between dermatologic immune-related adverse event morphologies and systemic immunomodulatory/immunosuppressive treatment: A large retrospective cohort study.

Rachel M Reardon, Katherine L Perlman, Maria S Asdourian, Nishi Shah, Ted V Jacoby, Leah L Thompson, Kerry L Reynolds, Yevgeniy R Semenov, Steven T Chen

Abstract readLetter
In one paragraph

Article in Journal of the American Academy of Dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rachel M ReardonDepartment of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
Katherine L PerlmanDepartment of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; University of Illinois College of Medicine, Chicago, Illinois.
Maria S AsdourianDepartment of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
Nishi ShahDepartment of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Ted V JacobyDepartment of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Leah L ThompsonDepartment of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Kerry L ReynoldsDivision of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
Yevgeniy R SemenovDepartment of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Steven T ChenDepartment of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: stchen@partners.org.

Funding

Predictive modeling of cutaneous immune checkpoint inhibitor toxicitiesK23AR080791 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI Yevgeniy R Semenov · 2023 to 2026
$704k
NCI NIH HHS L30 CA264747NIAMS NIH HHS K23 AR080791
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Immunosuppressive AgentsAdultAgedDrug EruptionsFemaleHumansImmunomodulating AgentsMaleMiddle AgedRetrospective StudiesSkin DiseasesImmunomodulating AgentsImmunosuppressive Agentsdermatologic immune-related adverse eventsimmune checkpoint inhibitorimmunotherapyoncology

Identifiers

PMID38341147
PMCPMC11749025

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.